Shares of Virax Biolabs Group Limited (NASDAQ:VRAX) surged 100% on Thursday following the announcement of an exclusive multi-country commercial supply agreement with Fosun Diagnostics for Virax's ImmuneSelect immune profiling product line.
The arrangement spans six Southeast Asian markets - Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia - and creates a framework for immediate product deliveries under purchase orders. Company statements indicate the agreement is intended to support near-term revenue generation while enabling regional commercial rollout.
ImmuneSelect is described by Virax as a commercially available, research-use-only immune profiling product line. It is distinct from ViraxImmune, the firm’s diagnostic platform that remains in clinical and regulatory development.
Under the terms of the agreement, Virax will provide ImmuneSelect immune profiling products to Fosun Diagnostics, including ELISpot assay plates that are used to measure cellular immune responses. Supply will be executed under purchase orders and pricing will include volume-based tiers, reflecting scalable commercial economics across the ASEAN region.
Virax and Fosun Diagnostics have identified an initial application focus on tuberculosis-related research in Thailand. Fosun has reported near-term customer demand there through the regional network of Fosun Pharma, and the companies noted potential subsequent rollouts into the other five countries covered by the agreement.
Fosun Diagnostics serves as the core diagnostics entity within Fosun Medtech, itself a division of Fosun Pharma. Fosun Pharma reported 2025 revenue of RMB41.662 billion, approximately $5.8 billion.
The commercial framework is designed to allow expansion beyond the initial product set, accommodating higher-volume supply arrangements and potential original equipment manufacturer or private-label opportunities. The exclusivity element of the agreement is conditioned on agreed minimum purchase and performance requirements.
This supply agreement links immediate order-backed sales potential with a structured path to broader regional distribution, while preserving separation between Virax’s current research-use offerings and its diagnostic platform that is still under development.
Context and implications
- Immediate deliveries under purchase orders are expected to produce near-term revenue opportunities.
- Volume-tiered pricing is intended to provide scalable margins as volumes increase across the ASEAN footprint.
- Initial demand is centered on tuberculosis-related research in Thailand, with potential expansion to Vietnam, Indonesia, the Philippines, Singapore and Malaysia.